Is the period of use of Deuterocolexitinib/Sondido longer than two months?

Plaque psoriasis is a chronic immune-related disease that often requires long-term management. Patients often ask when using new drugs:" Is the medication period of Deucravacitinib longer than two months?" This question actually reflects patients' concerns about the sustainability and safety of the efficacy. According to overseas authoritative information and clinical practice experience, deuterated coxitinib is indeed not a drug for short-term use, but is intended for medium- and long-term management.

Generally speaking, psoriasis patients can see significant improvement in skin lesions within the first two months of taking the drug, which is closely related to the inhibitory effect of the drug on inflammatory signaling pathways. But in order to maintain efficacy and reduce recurrence, treatment usually does not stop immediately after two months. Unlike some drugs that require short-term impact, deuterated colexitinib is more suitable for maintenance treatment, that is to say, its treatment cycle often exceeds two months, and even needs to be extended to half a year or more depending on the patient's condition.

From the perspective of clinical application, doctors will formulate a course of treatment based on the severity of the patient's condition, previous medication history, and therapeutic response. For patients with moderate to severe psoriasis, stopping the medication too early may lead to a rapid relapse of the disease, so in most cases it is recommended to continue taking the medication after the initial effect is apparent. Because deuterated colexitinib has a relatively controllable safety profile, it offers patients the possibility of long-term use.

It needs to be emphasized that this "long-term" does not mean unlimited, but requires dynamic adjustment under the guidance of professional doctors. For some patients, after their disease is well controlled, doctors may recommend extending the dosing interval or discontinuing medication for observation based on the situation. In contrast, traditional hormone therapy is often not suitable for long-term use due to side effects, and deuterated coxitinib just fills this gap.

Reference materials:https://go.drugbank.com/drugs/DB16650